Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | NKTR-262 |
Trade Name | |
Synonyms | NKTR262|NKTR 262 |
Drug Descriptions |
NKTR-262 is small molecule that targets the Toll-like receptor 7/8 pathway, triggering an innate immune response and the release of tumor antigens, which potentially leads to tumor regression when combined with a checkpoint inhibitor (Journal for ImmunoTherapy of Cancer 2017, 5 (Suppl 2):87 #P275). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C148289 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Nivolumab + NKTR-214 + NKTR-262 | NKTR-214 NKTR-262 Nivolumab | 0 | 1 |
NKTR-214 + NKTR-262 | NKTR-214 NKTR-262 | 0 | 1 |
NKTR-262 | NKTR-262 | 0 | 0 |